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ObjectiveaaPatients diagnosed with schizophrenia have reduced fecundity and premature mortality (both accidental and violent) with 
no obvious compensatory advantages among kin. The prevalence of the disorder is around 0.7/1%, higher than the expected prevalence 
of spontaneous mutations. Genes favoring schizophrenia may have been positively selected in the environment of evolutionary adapta-
tion. Literature on potential adaptive genes is reviewed within an evolutionary framework.
MethodsaaLiterature search on major scientific search engine (PubMed/Medline, Ovid/PsychInfo) on papers aimed at investigating 
potential pathways justifying a mutation-selection balanced model. Findings are presented with a narrative touch to favor readability 
and understanding. 
ResultsaaReduced incidence of cancer in both patients diagnosed with schizophrenia and their siblings was reported worldwide. Such 
findings are notable given higher cancer risk factors in schizophrenia, i.e., smoking, alcohol abuse, obesity, poor diet, and poor adher-
ence to therapy. Some genes involved in cancer proliferation might as well confer protective advantage in immune-surveillance, inflam-
mation, vascular proliferation or apoptosis that otherwise will adversely affect early neurodevelopment.
ConclusionaaEvidence that reduced risk of certain somatic diseases is associated with schizophrenia is quite significant to progress in 
the evolutionary epidemiological analysis of psychopathology.  Psychiatry Investig 2011;8:77-88
Key Wordsaa  Schizophrenia, Etiology, Evolutionary epidemiology, Obstetric complications, Cancer, Immune system.
INTRODUCTION
Recently Joo and co-workers
1 reported an association be-
tween single nucleotide polymorphisms in the V-akt murine 
thymoma viral oncogene homolog 1 (AKT1) gene and risk of 
obstetric complications in a large sample (n=180) of patients di-
agnosed with schizophrenia. The findings were open to inter-
pretation, since they were statistically significant in female pa-
tients only and did not survive a correction for multiple testing. 
However, they add to a growing literature showing links be-
tween genes, schizophrenia and risk for somatic illness are 
more complicated than currently thought.
2,3 The role of ob-
stetric complications in schizophrenia is still debated.
4 Meta-
analyses generally establish a link between obstetric complica-
tions and schizophrenia.
5 Likewise, the suggested reduced risk 
of cancer in patients diagnosed with schizophrenia is still debat-
ed.
6,7 We think that an evolutionary epidemiological analysis 
can help better assess these issues.
8
Evolutionary epidemiology looks for explanation of the per-
sistence of genetically based traits that are maladaptative in 
terms of survival and fertility.
9,10 Schizophrenia is a serious, 
chronic disorder, which negatively impacts the lives of affected 
patients, their families as well as society at large. The clinical 
course is typified by highly recurrent acute episodes with chron-
ic impairment of social, vocational, and personal well-being.
11-13 
The costs for patients, their families and society are huge.
14,15 
More complete knowledge of the etiology of this disorder mi-
ght lead to earlier detection of symptoms, more effective treat-
ments and, ideally, directly preventative interventions. Such a 
complete understanding will entail not only analyses of com-
plex ontogeny but also more intensive study of the phylogenet-
ics of schizophrenia.
Recent systematic meta-analyses of studies of the epidemi-
ology of schizophrenia reported a median incidence of 15.2/ 
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100,000 persons (80% CI=7.7-43.0), and a median prevalence 
of 4.0/1,000 persons (80% CI=1.8-11.6), with a lifetime mor-
bidity risk of 7.2/1,000 persons.
16 The risk is higher among males 
than females, with a risk ratio=1.4/1. 
Family, twin, and adoption studies of schizophrenia confirm 
a significant but not complete hereditary basis. Odds ratio of 
familial aggregation of schizophrenia is quite high, on average 
6 to 15.
17 In adoption, the risk is consistently higher in biolog-
ical versus adoptive clusters.
18 In twins, the risk is higher among 
monozygotic than dizygotic pairs. Genetic heritability attribut-
able to non-shared environment is estimated at 81%, with a sc-
ant 11% attributable to environmental effects shared by the 
members of a twin pair.
19,20  
However, the genetics of schizophrenia remain far from clear. 
According to a synthesis prepared by Gottesman and Erlenmey-
er-Kimling,
21 prevalence is consistently higher among first-de-
gree relatives of patients-from 6% of parents to 13% of offspring. 
However, up to 63% of patients have no first- or second-degree 
relative with the disorder. Moreover, the prevalence of schizo-
phrenia is 48-53% among monozygotic twins (as against 15-17% 
in dizygotic twins). 
Additional factors have been reported to be involved in the 
etiology and developmental onset of schizophrenia, notably pla-
ce or time of birth, infections during pre- and peri-natal devel-
opment, obstetric complications during pregnancy or labor (Ta-
ble 1). Nevertheless, a family history of psychosis is still by far 
the strongest predictor of schizophrenia in a given subject.
22-24  
What is schizophrenia, really?
Despite a century of investigation, diagnosis of schizophre-
nia relies solely on clinical evaluation of symptoms, with no re-
liable laboratory test to distinguish affected patients from heal-
thy people. Indeed, there is good evidence for global alterations 
in brain structure and subtle abnormalities in physiological and 
neurochemical functioning, but few are specific to schizophre-
nia or have sufficient effect size to allow diagnosis differenti-
ation.
25 Over time, this difficulty has led to increasingly nihilis-
tic positions, such as claims that schizophrenia is not a distinct 
or coherent nosological entity but an epistemological delusion 
without a real basis in nature.
26 Others propose to subsume sc-
hizophrenia into a more general class of psychosis, or meld it 
within an even more general affective-psychotic continuum.
27-29 
Clearly, lack of external validators seriously hampers the inves-
tigation of the epidemiological, clinical and neurobiological co-
rrelates of the disorder. 
MORBIDITY AND MORTALITY 
IN SCHIZOPHRENIA
Current criteria for diagnosis of schizophrenia refer to a pro-
totypical condition subdivided into variants based on associate 
symptoms, clinical course, and response to treatment, among oth-
er considerations.
30 Patients diagnosed with schizophrenia by 
current criteria suffer a higher risk of premature mortality-they 
die much earlier on a modal basis compared to the life expec-
Table 1. Factors related to the risk of schizophrenia in adulthood 
Place/Time of birth Higher incidence associated to urbanization  Ref. 168,169,170
Higher incidence associated to migration Ref. 171,172,173
Slight excess in winter/spring born Ref. 23,174,175 
Infections  Influenza Ref. 176,177,178 
Rubella Ref. 179
Poliovirus Ref. 180 
Toxoplasmosis Ref. 181,182
CNS infections Ref. 183,184 
Pre-/Perinatal factors  Famine Ref. 185,186,187 
Maternal stress by flood Ref. 188
Maternal depression Ref. 189 
Other maternal stress Ref. 190,191,192
Obstetric complications  Rh incompatibility Ref. 115,116  
Hypoxia Ref. 5,193,194
CNS damage/Low birth weight Ref. 195,196,197
Preeclampsia Ref. 198,199
Family history  Significant familial aggregation Ref. 22,23,24
Increased risk in biological vs. adoptive parents Ref. 18
Higher risk in monozygotic vs. dizygotic twins Ref. 19,200,201 A Preti & DR Wilson 
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tancy of the general population. These risks are higher for both 
natural
13,31 and violent causes,
32 particularly suicide.
33 
Higher risk of premature mortality in patients with schizo-
phrenia depends on increased incidence of somatic diseases 
in these patients, largely as a consequence of psychopathology.
12 
A higher risk has been reported for infections such as tubercu-
losis and virus disease
34-36 respiratory tract diseases,
37 nutrition-
al and metabolic disorders
38-40 and cardiovascular disease.
41,42 
Even adjusted mortality due to poor dental hygiene among per-
sons poses an important burden on patients suffering schizo-
phrenia.
43,44 The main causes of greater rates and severity of so-
matic diseases in patients diagnosed with schizophrenia inclu-
de unhealthy lifestyle and poor adherence to treatment, nota-
bly medication.
45,46 Conversely, the often-significant adverse 
consequences of prescribed antipsychotic therapy directly in-
crease a number of serious illnesses, notably the ‘metabolic 
syndrome’.
47-49 Yet some recent studies and meta-analyses indi-
cate patients diagnosed with schizophrenia have a reduced in-
cidence of cancer and neoplasms.
7,50-53 Such a reduced risk of can-
cer in patients strongly suggests that somatic factor(s) co-occu-
ring with schizophrenia are protective against cancer. 
Inclusive fitness in schizophrenia
From an evolutionary point of view, survival is not merely 
due to adaptation to the environment. In Darwinian terms, in-
dividual fitness refers to differential replication of one’s genes in 
the next generation, that is, mating success. The ability to rear 
offspring is essential in achieving individual fitness. Ultimate-
ly, individual fitness entails:
1) securing nutrients and other resources for survival, 
2) avoidance of death before reproduction, and 
3) finding mates to beget offspring, and then 
4) rearing of them until sexual maturity and reproduction 
of the lineage. 
The increase in the number of one’s genes in subsequent gen-
erations also includes non-offspring kin, as a function of the per-
centage of genes by direct descent from a common ancestor. 
This is inclusive fitness, which refers to the total replication of 
genes in the subsequent generation via both direct (offspring) 
and indirect (kin) carriers.
54,55
Some older studies reported a trend towards higher fertili-
ty rates in patients’ relatives.
56,57 On the other hand, most stud-
ies have reported lower fertility rates in schizophrenia,
58-60 and 
no compensatory fertility in relatives.
61,62 Clinical experience is 
that patients suffering from severe mental disorders tend to have 
a lower chance of mating-social incapacities form barriers to the 
tasks of finding a partner, having children, and then rearing 
them to maturity. The practice of detaining patients with severe 
mental disorders in locked mental health hospitals surely con-
tributed to reduce their reproductive opportunities. Studies on 
this non-secondary aspect of the life of patients with schizophre-
nia are pending in countries where provision of care for patients 
with mental disorders is covered by networks of community 
mental health outpatient centers that have expanded as hospi-
tals closed.
63 
The paradox of a disorder with a general population preva-
lence of nearly 1%, with a robust genetic basis, but lower fecun-
dity and no fertility compensatory advantage in relatives, taken 
together suggests that the genetic aberration linked to this ill-
ness must also carry with it a heretofore unrecognized evolution-
ary advantage.
64 As yet, attempts to identifying any unrecog-
nized evolutionary advantages have been challenging and largely 
unsatisfactory. However, factors linked to reduced risk of can-
cer could have been a powerful selective advantage in phylogeny. 
CANCER AND SCHIZOPHRENIA
In a recent meta-analysis, Catts et al.
7 found that the over-
all cancer incidence rates in patients suffering from schizophre-
nia were not significantly higher than those in the general pop-
ulation. This was despite the high load of risk factors for can-
cer among patients with schizophrenia, including smoking, 
alcohol abuse, obesity, poor diet, and non-adherence to medi-
cal advice. Indeed Catts et al.
7 found a reduced risk of colorec-
tal cancer, malignant melanoma, and prostate cancer among 
patients with schizophrenia compared to the general popula-
tion, and a reduced impact of smoking on lung and bladder can-
cer risks. 
Remarkably, that patients suffering from schizophrenia have 
a lower risk of cancer is a long-recognized feature of the disor-
der,
65 with reports as early as 1909,
66 although such reports do 
not constitute a consensus.
67 While important negative results 
have been reported, other surveys describe an enhanced, rath-
er than decreased, cancer risk among patients diagnosed with 
schizophrenia.
6,68 Nevertheless, patients with schizophrenia tend 
to be early, heavy, and long-term smokers of cigarettes;
69,70 so, 
much higher rates of cancer among persons with schizophrenia 
ought to be evident given such exposure to a recognized risk fac-
tor for many types of cancer.
71 Beyond smoking as a major risk 
factor, such patients are less able to pay proper attention to 
other broad health factors, notably a balanced diet or regular 
exercise. Moreover, high rates of substance use disorder that co-
occur with schizophrenia are an additional source of cancer 
risk.
72-74 
Smoking, alcohol use, and life-style differences are not the 
only explanations for the distinct differences in cancer preva-
lence noted within the general population. Exposure to car-
cinogenic chemical compounds in the workplace could repre-
sent a greater risk factor for some types of cancer than smoking 
or eating less fruit and vegetables than suggested by current 80  Psychiatry Investig 2011;8:77-88
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health guidelines.
75,76 If so, persons with schizophrenia, by in-
ference from their much higher rates of unemployment, may be 
expected to have fewer cancers. Similarly, some have posited 
that antipsychotic pharmacotherapy itself may have both di-
rect
77,78 and indirect anticancer effects (such as hormonal mod-
ulation by dopamine). These might contribute to the lower rate 
of cancer occurrence in schizophrenia.
79,80 Indeed, perhaps the 
best evidence of lower risk in patients with schizophrenia is with 
prostate cancer,
81 a condition considerably influenced by hor-
mones affected by antipsychotic drugs. In the aging male, pros-
tate cancer occurs more commonly amid rising levels of estro-
gen and decreasing levels of androgen.
82 The prolactin-induc-
ing property of most antipsychotic drugs has a subsequent 
negative feedback on estrogen levels.
83 This might reduce risk of 
prostate cancer in patients treated with antipsychotic drugs, de-
spite representing per se a risk factor for other types of cancer.
84 
On the other hand, rates of breast cancer are increased in wom-
en with schizophrenia but at a rate lower than expected from 
known risk factors; among others, null-parity, obesity, poor diet, 
and hyperprolactinemia related to antipsychotic medication 
exposure.
7 
The pathways to reduced risk of cancer in schizophrenia are 
manifold. Cancers are conditions often occurring in later life. 
Causes of death exclude each other: someone who dies by sui-
cide cannot die by cancer. Since patients with schizophrenia of-
ten die at a younger age than the general population, they may 
not have the time to develop certain cancers. Psychiatric patients 
might be less likely to be screened for cancer, or may be more 
frequently lost in follow-up, and also were known to be less like-
ly to report physical symptoms,
85 though patients rarely ignore 
advanced symptoms of cancer, such as pain. Finally, the epigene-
tics and epiphenemics of schizophrenia itself may confer some 
kind of genetic protection against cancer. 
A role for genetics
A recent report from Israel offers clear evidence that the low-
er risk of cancer extends to patients’ close kin. Both the par-
ents and siblings of subjects with schizophrenia had a statisti-
cally significant lower risk of cancer, with the clearest evidence 
noted in reduced cancers of the breast and prostate.
86 These Is-
raeli findings parallel a prior publication of a national cohort of 
individuals born in Finland between 1940 and 1969 who were 
treated for schizophrenia between 1969 and 1991.
6 However, 
another population study carried out on the Danish Central Reg-
istries on Psychiatry and Cancer reported negative findings.
87
With respect to the Israeli study, the lower risk of morbidity 
for cancer in both index cases and blood relatives strongly po-
ints to a genetic influence. The patient group, less likely to have 
a job, is perhaps less exposed to chemical carcinogenic com-
pounds and/or may gain some benefit from as yet unknown 
protective effects of antipsychotic medications. However, such 
mechanisms cannot account for the reduced risk in their blood-
kin. It is unclear if patients’ relatives are more health-conscious 
than the affected kin, i.e., smoke less than the general popu-
lation, as this has not been studied. It is pertinent that the Israeli 
study did tally schizophrenia diagnoses in the sample of relatives 
and the exclusion of those with schizophrenia did not change 
the findings. Healthy parents and siblings of patients with sc-
hizophrenia still showed a lower risk of cancer than the com-
parison group. 
There are few doubts that genetics plays a relevant role in in-
creasing, or decreasing, the risk of cancer within components 
of the general population.
88-90 Some studies suggest very simple 
genetic mechanisms may have a major role in many familial 
cancers;
91,92 the Lynch Syndrome was perhaps the first confir-
mation of a mendelian cancer, in the colon.
93,94 So too, yet un-
known genetic factors linked to the reduced risk of cancer in sc-
hizophrenia could have a role in the etiology of the disorder. 
GENETICS, OBSTETRIC 
COMPLICATIONS, AND 
SCHIZOPHRENIA: THE MISSING LINK?
The etiology of schizophrenia remains unknown, and its ge-
netics is quite puzzling: heritability is 70-85%, yet 60% of the 
people diagnosed with schizophrenia have neither a first, nor a 
second-degree affected relative.
21,95 Moreover, concordance in 
twins oscillates between 15 and 58%
21,96 indicates some role for 
post-translational epigenetic factors.
97,98 Large-scale surveys 
have identified a wide range of susceptibility genes,
99 but the 
specificity of these genes to schizophrenia is questionable, and 
attempts to replicate findings were often unsuccessful.
100,101 
While it is unlikely a single gene is responsible for schizophre-
nia, the issue is clouded by vast problems in proper clinical de-
scription of a true epigenetic phenotype that is separable from 
similar acquired syndromes.
8
Drawing from past formulations,
10,64 an oligogenic, mutation-
selection balance model has been proposed to explain incon-
sistencies in the identification of susceptibility genes in schizo-
phrenia. In this model, a relatively small number of alternative 
alleles are maintained because their net fitness effects balance 
each other, so the alleles are not lost by chance or genetic dri-
ft.
102,103 Such a mechanism could imply some gene-environ-
ment interaction,
104,105 whereby a genetic profile is associated 
with an enhanced risk of suffering from adverse events on a neu-
rodevelopment basis (Figure 1). 
Studies of both animals and humans point to the possibili-
ty environmental events might impact genetic predisposition to 
abnormal reactions after CNS lesion, causing deviations in the 
natural course of brain maturation that may result in neuropsy-A Preti & DR Wilson 
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chiatric disorders.
106-110 Pre-/Peri-natal complications are th-
ought to disrupt normal fetal brain development, thus disor-
ganizing both the cerebral micro-architecture and neural net-
work interlacement. Pre-/Peri-natal complications most often 
associated with schizophrenia in general lead to hypoxic-isch-
emic damage.
5 However, major fetal brain anoxia - likely to re-
sult from severe obstetric complications - generally leads to dea-
th or to marked motor impairment.
111,112 Therefore, we infer that 
some brain-protecting gene would be necessary to balance the 
brain-damaging impact of severe obstetric complications: when-
ever obstetric complications occur, schizophrenia would devel-
op only in the presence of the protective gene.
105 However, even 
less severe obstetric complications may cause deviation in neuro-
development when alleles enhancing the impact of these obstet-
ric events are present, and again the co-occurrence of brain-pro-
tecting gene would prevent the worst consequences of the resulting 
brain damage (death or severe cognitive or motor impairment). 
A link between obstetric complications and schizophrenia 
is now well established and the effect is small, but consis-
tent.
113,114 Past studies found that certain epigenetic conditions 
increasing the risk of obstetric complications are also associat-
ed with a higher risk of schizophrenia, e.g., Rh-incompatibili-
ty.
115,116 Obstetric complications also tend to recur within fami-
lies and cluster in families with a larger number of subjects 
diagnosed with schizophrenia.
117 In addition, mothers of chil-
dren who later suffer from schizophrenia themselves have en-
hanced risk of unfavorable outcome in pregnancies other than 
the index case.
118 Conversely, siblings of patients with schizo-
phrenia incur greater frequency and severity of pregnancy and 
birth complication than do healthy controls.
119 
Such evidence suggests the genetics of schizophrenia might 
be explained, in part, by the related genetics of conditions that 
increase risk of obstetric complications.
105,120 Even where there 
is seemingly equal exposure to risk, as in the case of twins, one 
twin may actually be more at risk. Such variations may help ex-
plain the incomplete concordance of schizophrenia in identi-
cal twins. Indeed, McNeil and coworkers
121 noted that labor 
complications in monozygotic twins were significantly more fre-
quent in twins discordant for schizophrenia.
Thus a wide range of mechanisms - inflammatory, immune, 
and/or vascular basis - may be processes etiogenic of schizophre-
nia. These range from initial pre/peri-natal brain insults, to neu-
ronal reorganization and synaptic plasticity in adolescence (the 
“second hit” in Figure 1), and finally to the onset of psycho-
sis.
105,122,123 Though heavily genetic, schizophrenia is also subject 
to considerable environmental influence.
104,105 But, what kind 
of genes could be involved, both related to cancer and express-
ing some protective effect on the neurodevelopment? 
POTENTIAL PATHWAYS 
IN THE REDUCED RISK 
OF CANCER IN SCHIZOPHRENIA
In their attempt to explain the lower cancer risk in parents 
and siblings of patients with schizophrenia, Levav and co-work-
ers
86 hypothesized a role for the tumor suppressor p53 ge-
ne.
124,125 This gene is but the first of the many with possible im-
plications for reduced risk of cancer in schizophrenia. There are 
other candidate genes, including:
-Adenomatous polyposis coli gene, tumor suppressor that is 
significantly associated with schizophrenia;
126 
-The fragile site, aphidicolin type, common, fra(6)(q21) 
(FRA6F), a site of unusual chromosomal fragility, is likely to car-
ry a tumor suppressor gene in a region that also maps to a gene 
Figure 1. The “two/three-hits” neurodevelopmental hypothesis of schizophrenia.
Genetically-based anomaly
Step one Step two
Anomalous brain reorganization under normal 
  endocrine stimuli during adolescence [?]a
Effects of protective and aggravating genes
Increased dopaminergic sensitivity to stress [?]b
Effects of protective and aggravating genes
a) Ref. 122,123 
b) Ref. 202,203 
c) Ref. 204,205 
d) Ref. 206 
Onset
Stress [?]c
Drug use [? Cannabis]d
Abnormal brain development
Perinatal insult
Effects of protective and aggravating genes82  Psychiatry Investig 2011;8:77-88
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linked to hereditary schizophrenia;
127 
-Phosphatidylinositide 3-kinase-protein kinase B pathway 
genes are involved in cellular growth and proliferation. These 
activities are reduced in schizophrenia, which may logically 
protect against cancer;
2 
-Neuregulin-I/ErbB signalling system genes modulate cell 
proliferation, migration, differentiation, and survival or apop-
tosis.
128,129 Neuregulin-I attenuated signaling is seen in animal 
models of schizophrenia;
128,130
-Bombesin-activated pathway genes have bombesin-like 
peptides that act as growth factors in the pathogenesis of sever-
al human cancers.
131 Patients with schizophrenia have lower lev-
els of bombesin than do non-schizophrenic subjects;
132
-Neurotensin genes implied in the activity of antipsychotic 
drugs.
133 Neurotensin also down-regulates neuropeptides auto-
crine growth factors active in cancer lines.
Additional mechanisms may be involved. MicroRNAs - non-
coding RNA molecules thought to regulate expression of many 
mRNAs - are implicated in the etiology of several types of can-
cer and expressed at a lower level in patients with schizophre-
nia.
134 Likewise, short tandem repeat (STR) replacements in un-
translated sequence (UTR), putatively involved in both schizo-
phrenia and cancer.
135
THE ROLE OF DEVIANCE 
IN NEURODEVELOPMENT
Apart from cancer, people with schizophrenia not only have 
reduced prevalence of diabetes mellitus type 1
136 and rheuma-
toid arthritis
137,138 but both conditions are influenced by genes 
that control immune and inflammatory systems - genes that may 
also influence obstetric complications on neurodevelopment. 
Immune-mediated conditions share with schizophrenia a 
propensity to atypical handedness (increased left-handedness 
and/or mixed-handedness), which is associated with many neu-
rodevelopmental disorders.
139-141
Additionally, a wide range of genes can influence, positively 
or negatively, the chances of cancer development. These include 
genes involved in control of immune-surveillance,
142,143 inflam-
mation,
144-146 vascular proliferation,
147-149 and apoptosis.
128,150 
Most of these genes are also involved in neurodevelopment, 
guiding neuron proliferation and rearrangement. 
Nicodemus et al.
151 reported four genes - AKT1, brain-deriv-
ed neurotrophic factor (BDNF), glutamate receptor 3 (GRM3), 
and dystrobrevin-binding protein 1 (DTNBP1)-are potentially 
involved in hypoxia/ischemia and/or the integrity of cerebro-
vasculature structures. These four genes are expressed in a non-
random fashion among patients with schizophrenia who ex-
perienced obstetric complications during pregnancy. More-
over, these genes have a demonstrable neuroprotective role.
152 
The Nicodemus study is the first to assess a plausible hypothe-
sis of gene-by-environment interaction in schizophrenia risk. 
All these genes might exert their effects through the well-
known mechanisms of pleiotropy and epistasis,
153 as the same 
genes that protect the brain from excessive perinatal damage 
may also both foster later development of schizophrenia yet pro-
tect against cancer.
EVIDENCE FOR ADAPTIVE EVOLUTION 
OF GENES INVOLVED 
IN SCHIZOPHRENIA
Crespi and co-workers
154 found evidence of positive selec-
tion of genes involved in the etiology of schizophrenia. Hap-
Map-based analyses showed evidence for positive selection on 
14 genes associated with schizophrenia. Stronger statistical ev-
idence was noted for DTNBP1 and the GRM3. Positive selec-
tion was found in additional 4 genes in the human - compared 
to chimpanzee- or primate-origin lineages. These genes are neu-
regulin 1 (NRG1), proteolipid protein 1 (PLP1), tenascin XB 
(TNXB), tumour protein p53 (TP53). Also, the ‘disrupted in 
schizophrenia’ gene (DISC1) showed positive selection in the 
human lineage, with evidence of acceleration in the coding re-
gion repeatedly associated with schizophrenia.
154 
More recently, a meta-analysis of the SchizophreniaGene da-
tabase found 8 potential candidate genes whose polymorphisms 
are statistically associated with schizophrenia.
155 Some correlat-
ed to enhanced risk of schizophrenia in carriers: TP53, dopa-
mine receptor D4 (DRD4), 5,10-methylenetetrahydrofolate re-
ductase (MTHFR), protein phosphatase 3 [formerly 2B] cataly-
tic (PPP3CC), and gamma-aminobutyric acid A receptor, beta 
(GABRB2). Conversely, others were associated with reduced risk 
of schizophrenia: D-amino acid oxidase (DAO), solute carrier 
family 6 member 4 (SLC6A4, also known as 5-hydroxytrypta-
mine transporter or 5-HTT), and interleukin1 and beta propro-
tein (IL1B). This is fully compatible with the hypothesis that bo-
th protective and aggravating genes play a role in the etiology of 
schizophrenia.      
IMPLICATIONS FOR RESEARCH 
Neither reduced risk of cancer nor the recently reported re-
duced mortality by cerebrovascular incidents
13 cause genes etio-
genic of schizophrenia to persist in the general population. Can-
cer or stroke typically occur well after sexual maturation and 
the reproductive cycle so neither should impact inclusive fitness 
of the individual. Thus, evidence that schizophrenia confers re-
duced risk of certain somatic diseases, if confirmed, is highly sig-
nificant information for evolutionary epidemiological analyses. 
This association is presumably mediated by important genetic A Preti & DR Wilson 
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elements in systems that involve immune-surveillance, inflam-
mation, vascular proliferation or apoptosis. Moreover, the asso-
ciation points to pleiotropic or epistatic etiogenes that not only 
induce schizophrenia but also confer protective somatic effects 
evident after the onset of psychosis. Though rather complex as 
pleiotropy and epistasis ever are, such associations evidently 
conferred distinct adaptive advantages in the environment of 
evolutionary adaptation.
8  
Indeed, these genes might have contributed to speciation, by 
protecting the fetus brain from increasing risk of damage in 
early environment. Among major factors that confer to the hu-
man fetus a higher risk of injury and infection are: large ratio of 
fetal head to maternal pelvic outlet size, presentation in occipi-
tal position (rather than face up, as in the apes), and prolonged la-
bor and delivery in humans compared to other anthropoids.
156
As delineated in this and prior papers,
105,120 schizophrenia 
could only develop when environmental events impacting the 
fetus in pregnancy and the perinatum (that occur within still to 
be identified temporal windows), thereby affect specific regions 
of the developing brain in presence of protective genes which 
prevent death or severe motor or cognitive impairment. Schizo-
phrenia does not persist because it protects from cancer or st-
roke, but because genes that offer such somatic protection are 
essential in successful navigation of earlier developmental phas-
es where schizophrenia arises.  
However, it is unlikely schizophrenia has a single etiological 
cause. It is possible that schizophrenia-like syndromes follow-
ing obstetric complications merely converge in disrupting 
mechanisms implicated in other heritable forms of psychoses 
diagnosable as “schizophrenia” endophenotypes according cur-
rently shared criteria. Hemispheric lateralization is one notable 
example wherein developmental disruptions often give rise to 
psychosis.
157 Indeed, obstetric complications often result in ab-
normal hemispheric specialization
158-160 of the kind more often 
reported in schizophrenia.
161,162 
Evolutionary sciences in general and evolutionary psychiatry 
in particular are often criticized for lack of testable hypothe-
ses.
163 Yet practical, ethical study protocols are elusive.
8 Here we 
have integrated a body of evidence with direct clinical conse-
quences as well as importance to evolutionary interpretation. 
Moreover and of particular interest to skeptics of evolutionary 
epidemiological analyses, it is possible to test the pleomorphic 
and epistatic roles here proposed for genes linked to protection 
against cancer and schizophrenia. 
Patients with schizophrenia should be significantly more like-
ly to screen positive for hereditary disorders linked to increased 
risk of obstetric complications.
105 Conversely, persons born with 
hereditary disorders that may increase risk of obstetric compli-
cations may have higher prevalence of schizophrenia in their 
families. Moreover, persons who both suffer from schizophre-
nia and also experienced obstetric complications should have 
lower rates of some cancers. 
Genetic polymorphisms that increase chances of neoplasia 
should be less common among persons with schizophrenia and 
their families. Conversely, genetic polymorphisms that decrease 
chances of neoplasia should be more common among persons 
with schizophrenia and their families. Patients who suffer from 
schizophrenia should be found to down-regulate genes and sys-
tems that increase cell proliferation, migration, differentiation, 
and survival or apoptosis, hence increasing the chance of can-
cer. Finally, the relationships between cancer and schizophrenia 
may span a multitude of regulatory pathways and genetic poly-
morphisms. Thus a rational approach should focus on factors 
that are more likely to moderate the consequences of prenatal 
and perinatal complications. Here we posit that such specific fac-
tors involved in cancer development and proliferation are also 
likely to be important in the development of schizophrenia.
Some preliminary findings are consisting with these expec-
tations. The most common haplotype block of MET proto-on-
cogene (MET) is primarily linked to tumor metastasis. This hap-
lotype was found in patients with schizophrenia statistically 
less often than in healthy controls.
164 The Matrix metalloprotein-
ase-9 (MMP9), also known as gelatinase B, 92 kDa gelatinase, 
or 92 Da type IV collagenase, is involved in cancer and cardio-
vascular disorders. In particular, the functional -1562 C/T poly-
morphism of the MMP9 gene confer a higher risk of cardiac 
mortality and more severe progression of some type of cancer: 
a diminished frequency of the T allele of the MMP9 gene was 
reported in patients diagnosed with schizophrenia.
165 It is no-
table genes specifically disrupted in schizophrenia operate in in-
teracting pathways but most are related to the development of 
the neural and immune systems.
166,167 
Further investigation of the links between schizophrenia and 
cancer will reveal much about the etiology of psychosis and will 
also cast light on a variety of somatic illnesses associated with 
schizophrenia and cancer through pleomorphic and epistatic 
mechanisms. The discovery of pathways that lead from pre- and/
or peri-natal insult caused by obstetric complications onto the 
manifestation of schizophrenia should advance therapeutics as 
well. Such discoveries may facilitate preventive measures in early 
development and may also guide screening and treatment for 
those types of cancer with reduced incidence in schizophrenia. 
Presently, early evidence is most robust for a role of genes pro-
tective in cancer that increase risk of schizophrenia - and vice 
versa. More expansively, this evolutionary epidemiological ap-
proach will likely trace many new and unexpected medical-
psychiatric pleomorphies and epistases. 
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